IBDEI2V3 ; ; 04-FEB-2020
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,45652,1,3,0)
;;=3^Chronic Embolism/Thrombosis Unspec Vein
;;^UTILITY(U,$J,358.3,45652,1,4,0)
;;=4^I82.91
;;^UTILITY(U,$J,358.3,45652,2)
;;=^5007941
;;^UTILITY(U,$J,358.3,45653,0)
;;=I25.9^^172^2275^8
;;^UTILITY(U,$J,358.3,45653,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45653,1,3,0)
;;=3^Chronic Ischemic Heart Disease,Unspec
;;^UTILITY(U,$J,358.3,45653,1,4,0)
;;=4^I25.9
;;^UTILITY(U,$J,358.3,45653,2)
;;=^5007144
;;^UTILITY(U,$J,358.3,45654,0)
;;=D68.9^^172^2275^9
;;^UTILITY(U,$J,358.3,45654,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45654,1,3,0)
;;=3^Coagulation Defect,Unspec
;;^UTILITY(U,$J,358.3,45654,1,4,0)
;;=4^D68.9
;;^UTILITY(U,$J,358.3,45654,2)
;;=^5002364
;;^UTILITY(U,$J,358.3,45655,0)
;;=D68.8^^172^2275^10
;;^UTILITY(U,$J,358.3,45655,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45655,1,3,0)
;;=3^Coagulation Defects,Other Spec
;;^UTILITY(U,$J,358.3,45655,1,4,0)
;;=4^D68.8
;;^UTILITY(U,$J,358.3,45655,2)
;;=^5002363
;;^UTILITY(U,$J,358.3,45656,0)
;;=D68.318^^172^2275^11
;;^UTILITY(U,$J,358.3,45656,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45656,1,3,0)
;;=3^Hemorrhagic Disorder d/t Intrinsic Circ Anticoagulants
;;^UTILITY(U,$J,358.3,45656,1,4,0)
;;=4^D68.318
;;^UTILITY(U,$J,358.3,45656,2)
;;=^340504
;;^UTILITY(U,$J,358.3,45657,0)
;;=Z79.01^^172^2275^12
;;^UTILITY(U,$J,358.3,45657,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45657,1,3,0)
;;=3^Long Term (Current) Use of Anticoagulants
;;^UTILITY(U,$J,358.3,45657,1,4,0)
;;=4^Z79.01
;;^UTILITY(U,$J,358.3,45657,2)
;;=^5063330
;;^UTILITY(U,$J,358.3,45658,0)
;;=Z79.02^^172^2275^13
;;^UTILITY(U,$J,358.3,45658,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45658,1,3,0)
;;=3^Long Term (Current) use of Antithrombotics/Antiplatelets
;;^UTILITY(U,$J,358.3,45658,1,4,0)
;;=4^Z79.02
;;^UTILITY(U,$J,358.3,45658,2)
;;=^5063331
;;^UTILITY(U,$J,358.3,45659,0)
;;=D68.62^^172^2275^14
;;^UTILITY(U,$J,358.3,45659,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45659,1,3,0)
;;=3^Lupus Anticoagulant Syndrome
;;^UTILITY(U,$J,358.3,45659,1,4,0)
;;=4^D68.62
;;^UTILITY(U,$J,358.3,45659,2)
;;=^5002361
;;^UTILITY(U,$J,358.3,45660,0)
;;=I73.9^^172^2275^15
;;^UTILITY(U,$J,358.3,45660,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45660,1,3,0)
;;=3^Peripheral Vascular Disease,Unspec
;;^UTILITY(U,$J,358.3,45660,1,4,0)
;;=4^I73.9
;;^UTILITY(U,$J,358.3,45660,2)
;;=^184182
;;^UTILITY(U,$J,358.3,45661,0)
;;=Z86.79^^172^2275^16
;;^UTILITY(U,$J,358.3,45661,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45661,1,3,0)
;;=3^Personal Hx of Circulatory System Diseases
;;^UTILITY(U,$J,358.3,45661,1,4,0)
;;=4^Z86.79
;;^UTILITY(U,$J,358.3,45661,2)
;;=^5063479
;;^UTILITY(U,$J,358.3,45662,0)
;;=Z86.711^^172^2275^17
;;^UTILITY(U,$J,358.3,45662,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45662,1,3,0)
;;=3^Personal Hx of Pulmonary Embolism
;;^UTILITY(U,$J,358.3,45662,1,4,0)
;;=4^Z86.711
;;^UTILITY(U,$J,358.3,45662,2)
;;=^5063474
;;^UTILITY(U,$J,358.3,45663,0)
;;=Z86.718^^172^2275^18
;;^UTILITY(U,$J,358.3,45663,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45663,1,3,0)
;;=3^Personal Hx of Venous Thrombosis/Embolism
;;^UTILITY(U,$J,358.3,45663,1,4,0)
;;=4^Z86.718
;;^UTILITY(U,$J,358.3,45663,2)
;;=^5063475
;;^UTILITY(U,$J,358.3,45664,0)
;;=Z95.2^^172^2275^19
;;^UTILITY(U,$J,358.3,45664,1,0)
;;=^358.31IA^4^2
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI2V3 3769 printed Sep 23, 2025@20:12:25 Page 2
IBDEI2V3 ; ; 04-FEB-2020
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,45652,1,3,0)
+2 ;;=3^Chronic Embolism/Thrombosis Unspec Vein
+3 ;;^UTILITY(U,$J,358.3,45652,1,4,0)
+4 ;;=4^I82.91
+5 ;;^UTILITY(U,$J,358.3,45652,2)
+6 ;;=^5007941
+7 ;;^UTILITY(U,$J,358.3,45653,0)
+8 ;;=I25.9^^172^2275^8
+9 ;;^UTILITY(U,$J,358.3,45653,1,0)
+10 ;;=^358.31IA^4^2
+11 ;;^UTILITY(U,$J,358.3,45653,1,3,0)
+12 ;;=3^Chronic Ischemic Heart Disease,Unspec
+13 ;;^UTILITY(U,$J,358.3,45653,1,4,0)
+14 ;;=4^I25.9
+15 ;;^UTILITY(U,$J,358.3,45653,2)
+16 ;;=^5007144
+17 ;;^UTILITY(U,$J,358.3,45654,0)
+18 ;;=D68.9^^172^2275^9
+19 ;;^UTILITY(U,$J,358.3,45654,1,0)
+20 ;;=^358.31IA^4^2
+21 ;;^UTILITY(U,$J,358.3,45654,1,3,0)
+22 ;;=3^Coagulation Defect,Unspec
+23 ;;^UTILITY(U,$J,358.3,45654,1,4,0)
+24 ;;=4^D68.9
+25 ;;^UTILITY(U,$J,358.3,45654,2)
+26 ;;=^5002364
+27 ;;^UTILITY(U,$J,358.3,45655,0)
+28 ;;=D68.8^^172^2275^10
+29 ;;^UTILITY(U,$J,358.3,45655,1,0)
+30 ;;=^358.31IA^4^2
+31 ;;^UTILITY(U,$J,358.3,45655,1,3,0)
+32 ;;=3^Coagulation Defects,Other Spec
+33 ;;^UTILITY(U,$J,358.3,45655,1,4,0)
+34 ;;=4^D68.8
+35 ;;^UTILITY(U,$J,358.3,45655,2)
+36 ;;=^5002363
+37 ;;^UTILITY(U,$J,358.3,45656,0)
+38 ;;=D68.318^^172^2275^11
+39 ;;^UTILITY(U,$J,358.3,45656,1,0)
+40 ;;=^358.31IA^4^2
+41 ;;^UTILITY(U,$J,358.3,45656,1,3,0)
+42 ;;=3^Hemorrhagic Disorder d/t Intrinsic Circ Anticoagulants
+43 ;;^UTILITY(U,$J,358.3,45656,1,4,0)
+44 ;;=4^D68.318
+45 ;;^UTILITY(U,$J,358.3,45656,2)
+46 ;;=^340504
+47 ;;^UTILITY(U,$J,358.3,45657,0)
+48 ;;=Z79.01^^172^2275^12
+49 ;;^UTILITY(U,$J,358.3,45657,1,0)
+50 ;;=^358.31IA^4^2
+51 ;;^UTILITY(U,$J,358.3,45657,1,3,0)
+52 ;;=3^Long Term (Current) Use of Anticoagulants
+53 ;;^UTILITY(U,$J,358.3,45657,1,4,0)
+54 ;;=4^Z79.01
+55 ;;^UTILITY(U,$J,358.3,45657,2)
+56 ;;=^5063330
+57 ;;^UTILITY(U,$J,358.3,45658,0)
+58 ;;=Z79.02^^172^2275^13
+59 ;;^UTILITY(U,$J,358.3,45658,1,0)
+60 ;;=^358.31IA^4^2
+61 ;;^UTILITY(U,$J,358.3,45658,1,3,0)
+62 ;;=3^Long Term (Current) use of Antithrombotics/Antiplatelets
+63 ;;^UTILITY(U,$J,358.3,45658,1,4,0)
+64 ;;=4^Z79.02
+65 ;;^UTILITY(U,$J,358.3,45658,2)
+66 ;;=^5063331
+67 ;;^UTILITY(U,$J,358.3,45659,0)
+68 ;;=D68.62^^172^2275^14
+69 ;;^UTILITY(U,$J,358.3,45659,1,0)
+70 ;;=^358.31IA^4^2
+71 ;;^UTILITY(U,$J,358.3,45659,1,3,0)
+72 ;;=3^Lupus Anticoagulant Syndrome
+73 ;;^UTILITY(U,$J,358.3,45659,1,4,0)
+74 ;;=4^D68.62
+75 ;;^UTILITY(U,$J,358.3,45659,2)
+76 ;;=^5002361
+77 ;;^UTILITY(U,$J,358.3,45660,0)
+78 ;;=I73.9^^172^2275^15
+79 ;;^UTILITY(U,$J,358.3,45660,1,0)
+80 ;;=^358.31IA^4^2
+81 ;;^UTILITY(U,$J,358.3,45660,1,3,0)
+82 ;;=3^Peripheral Vascular Disease,Unspec
+83 ;;^UTILITY(U,$J,358.3,45660,1,4,0)
+84 ;;=4^I73.9
+85 ;;^UTILITY(U,$J,358.3,45660,2)
+86 ;;=^184182
+87 ;;^UTILITY(U,$J,358.3,45661,0)
+88 ;;=Z86.79^^172^2275^16
+89 ;;^UTILITY(U,$J,358.3,45661,1,0)
+90 ;;=^358.31IA^4^2
+91 ;;^UTILITY(U,$J,358.3,45661,1,3,0)
+92 ;;=3^Personal Hx of Circulatory System Diseases
+93 ;;^UTILITY(U,$J,358.3,45661,1,4,0)
+94 ;;=4^Z86.79
+95 ;;^UTILITY(U,$J,358.3,45661,2)
+96 ;;=^5063479
+97 ;;^UTILITY(U,$J,358.3,45662,0)
+98 ;;=Z86.711^^172^2275^17
+99 ;;^UTILITY(U,$J,358.3,45662,1,0)
+100 ;;=^358.31IA^4^2
+101 ;;^UTILITY(U,$J,358.3,45662,1,3,0)
+102 ;;=3^Personal Hx of Pulmonary Embolism
+103 ;;^UTILITY(U,$J,358.3,45662,1,4,0)
+104 ;;=4^Z86.711
+105 ;;^UTILITY(U,$J,358.3,45662,2)
+106 ;;=^5063474
+107 ;;^UTILITY(U,$J,358.3,45663,0)
+108 ;;=Z86.718^^172^2275^18
+109 ;;^UTILITY(U,$J,358.3,45663,1,0)
+110 ;;=^358.31IA^4^2
+111 ;;^UTILITY(U,$J,358.3,45663,1,3,0)
+112 ;;=3^Personal Hx of Venous Thrombosis/Embolism
+113 ;;^UTILITY(U,$J,358.3,45663,1,4,0)
+114 ;;=4^Z86.718
+115 ;;^UTILITY(U,$J,358.3,45663,2)
+116 ;;=^5063475
+117 ;;^UTILITY(U,$J,358.3,45664,0)
+118 ;;=Z95.2^^172^2275^19
+119 ;;^UTILITY(U,$J,358.3,45664,1,0)
+120 ;;=^358.31IA^4^2
